TAKEDA Pharmaceutical Company has announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to TAK-426.
TAK-426 is Takeda's purified, inactivated, alum-adjuvanted, whole Zika virus vaccine candidate.
The FDA's Fast Track designation is a process designed to facilitate the development and expedite the review of drugs and vaccines for serious conditions and that fill an unmet medical need.
Takeda's Zika vaccine candidate is currently being studied in a Phase 1 trial (ZIK-101) and if initial data is supportive, a phase 2 development will commence ASAP.
The above article was sent to subscribers in Pharmacy Daily's issue from 31 Jan 18
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 31 Jan 18
